CD20-negative t-cell-rich b-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximabL: A molecular analysis using laser capture microdissection

Lara Pijuan, Luis Vicioso, Beatriz Bellosillo, Maria Dolores Ferrer, Teresa Baró, Carme Pedro, Josep Lloreta-Trull, Assumpta Munné, Sergi Serrano

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

Abstract

Rituximab is a chimeric anti-CD20 monoclonal antibody. It has shown efficacy in patients with B-cell non-Hodgkin lymphoma and also in CD20-positive Hodgkin lymphoma. Recently, CD20-negative tumors have been described after Rituximab therapy. We report a 34-year-old man with a history of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), treated with different chemotherapy regimens, including anthracyclines and Rituximab. After 4 years in complete remission, he developed a CD20-negative T-cell-rich B-cell lymphoma (TCRBCL) presenting as multiple lung lesions. This case shows the difficulties in the diagnosis of CD20-negative lymphomas when the number of tumor cells is low and when they are found in a predominant T-cell context. Using anti-CD79a as a B-cell marker is mandatory to overcome the difficulties in identifying these tumors. Moreover, this case illustrates the usefulness of laser capture microdissection to obtain purified cell populations for molecular studies in lymphomas with relative paucity of tumor cells, as well as the need to analyze different IgH gene regions to decrease the rate of false-negative results in PCR clonality studies. Copyright © 2005 by Lippincott Williams & Wilkins.
Original languageEnglish
Pages (from-to)1399-1403
JournalAmerican Journal of Surgical Pathology
Volume29
DOIs
Publication statusPublished - 1 Oct 2005

Keywords

  • CD20-negative B-cell lymphoma
  • Nodular lymphocyte-predominant hodgkin's lymphoma
  • PCR
  • Rituximab
  • T-cell rich B-cell lymphoma

Fingerprint Dive into the research topics of 'CD20-negative t-cell-rich b-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximabL: A molecular analysis using laser capture microdissection'. Together they form a unique fingerprint.

Cite this